Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.

European journal of nuclear medicine and molecular imaging - 1 Jul 2026

Stien Guilhem, Obara Tiphaine, Truong Mike, Zaragori Timothee, Blonski Marie, Taillandier Luc, Verger Antoine

Abstract excerpt

PURPOSE: Mutant IDH (mIDH) inhibitors represent a novel therapeutic approach for IDH-mutant gliomas. This study aimed to evaluate the role of amino acid PET in monitoring the response to mIDH inhibitor treatment in patients with refractory IDH-mutant gliomas. METHODS: Patients with confirmed IDH-mutant gliomas who received mIDH inhibitor treatments, ivosidenib or vorasidenib, between February 2022 and November...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Positron-Emission Tomography

Share to Treatment Outcome

Source

Identifiers

PMID: 41995839
DOI: 10.1007/s00259-026-07895-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas.PMID 41995839Read ↗

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.Semantic proximity Read ↗

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.Semantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomasSemantic proximity Read ↗

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Semantic proximity Read ↗

Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study.Semantic proximity Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.